C0005516||Biomarkers
C0243095||clinical manifestations
C0002986||Fabry disease
C1522601||cardiac
C0026882||mutation
C0002986||Fabry disease
C0085078||lysosomal storage disorder
C0678941||IVS4+919G>A
C1522601||cardiac
C0026882||mutation
C0039260||Taiwan
C0037088||Signs and symptoms
C1522601||cardiac
C0149721||left ventricular hypertrophy
C0026266||mitral insufficiency
C0003811||arrhythmias
C0005516||biomarkers
C0087111||treatment
C0002986||Fabry disease
C0005516||biomarkers
C0061338||globotriaosylceramide
C0061338||Gb3
C0082711||globotriaosylsphingosine
C0082711||lyso-Gb3
C0243071||analogues
C0243102||enzyme activity
C0243095||clinical manifestations
C0012634||disease
C0042036||Urine
C0032105||plasma
C0005516||biomarkers
C0936012||analyzed
C0599748||tandem mass spectrometry
C0599755||cohort
C0002986||Fabry
C0678941||IVS4+919G>A
C0026882||mutation
C2603343||studied
C0032105||plasma
C0082711||lyso-Gb3
C0243071||analogue
C0082711||lyso-Gb3
C1514241||positive
C0243095||left ventricular mass index
C0543488||interest
C0150369||monitor
C0005516||biomarkers
C0023981||longitudinal study
C0221102||excretion
C0012634||disease